WO2015051762A1 - 马沙骨化醇的合成中间体及其制备方法和用途 - Google Patents
马沙骨化醇的合成中间体及其制备方法和用途 Download PDFInfo
- Publication number
- WO2015051762A1 WO2015051762A1 PCT/CN2014/088336 CN2014088336W WO2015051762A1 WO 2015051762 A1 WO2015051762 A1 WO 2015051762A1 CN 2014088336 W CN2014088336 W CN 2014088336W WO 2015051762 A1 WO2015051762 A1 WO 2015051762A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- borane
- reaction
- protecting group
- Prior art date
Links
- DTXXSJZBSTYZKE-ZDQKKZTESA-N Maxacalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](OCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C DTXXSJZBSTYZKE-ZDQKKZTESA-N 0.000 title claims abstract description 18
- 229950006319 maxacalcitol Drugs 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims description 18
- 150000001875 compounds Chemical class 0.000 claims abstract description 128
- 238000000034 method Methods 0.000 claims abstract description 54
- 230000001590 oxidative effect Effects 0.000 claims abstract description 3
- 238000006243 chemical reaction Methods 0.000 claims description 61
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 claims description 46
- 229910000085 borane Inorganic materials 0.000 claims description 23
- 125000006239 protecting group Chemical group 0.000 claims description 20
- 230000008569 process Effects 0.000 claims description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 claims description 10
- 239000003054 catalyst Substances 0.000 claims description 8
- 238000007254 oxidation reaction Methods 0.000 claims description 8
- KLNAKPRPVCQFAW-UHFFFAOYSA-N 3-(bromomethyl)-2,2-dimethyloxirane Chemical compound CC1(C)OC1CBr KLNAKPRPVCQFAW-UHFFFAOYSA-N 0.000 claims description 7
- 230000009467 reduction Effects 0.000 claims description 7
- -1 triethylsilyl Chemical group 0.000 claims description 7
- 230000009471 action Effects 0.000 claims description 6
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 5
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 229910052744 lithium Inorganic materials 0.000 claims description 5
- 239000007800 oxidant agent Substances 0.000 claims description 5
- 230000003647 oxidation Effects 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 238000006552 photochemical reaction Methods 0.000 claims description 4
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 claims description 4
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- 239000010949 copper Substances 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 claims description 2
- KHYAFFAGZNCWPT-UHFFFAOYSA-N boron;n,n-diethylaniline Chemical compound [B].CCN(CC)C1=CC=CC=C1 KHYAFFAGZNCWPT-UHFFFAOYSA-N 0.000 claims description 2
- VEWFZHAHZPVQES-UHFFFAOYSA-N boron;n,n-diethylethanamine Chemical compound [B].CCN(CC)CC VEWFZHAHZPVQES-UHFFFAOYSA-N 0.000 claims description 2
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 claims description 2
- LDOCXVBFUHZGBF-UHFFFAOYSA-N copper;2-pyridin-2-ylpyridine Chemical group [Cu].N1=CC=CC=C1C1=CC=CC=N1 LDOCXVBFUHZGBF-UHFFFAOYSA-N 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 5
- 125000001033 ether group Chemical group 0.000 claims 1
- 229920001296 polysiloxane Polymers 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 16
- 230000002194 synthesizing effect Effects 0.000 abstract description 5
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 abstract description 4
- 229960002061 ergocalciferol Drugs 0.000 abstract description 4
- 235000001892 vitamin D2 Nutrition 0.000 abstract description 4
- 239000011653 vitamin D2 Substances 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 3
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 abstract description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 101100132433 Arabidopsis thaliana VIII-1 gene Proteins 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N CHCl3 Substances ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 230000035484 reaction time Effects 0.000 description 8
- 0 C[C@@](CCC1)([C@](CC2)C(C)=O)[C@@]2C1=C[C@@](C1=C(C2)CC[C@](*)C1)S2(=O)=O Chemical compound C[C@@](CCC1)([C@](CC2)C(C)=O)[C@@]2C1=C[C@@](C1=C(C2)CC[C@](*)C1)S2(=O)=O 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 238000006722 reduction reaction Methods 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 3
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical group [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000007086 side reaction Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical group [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000011916 stereoselective reduction Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- DTXXSJZBSTYZKE-WFNAWOCOSA-N C[C@@H]([C@@H](CC1)[C@@](C)(CCC2)[C@@H]1/C2=C/C=C(\C[C@H](C[C@@H]1O)O)/C1=C)OCCC(C)(C)O Chemical compound C[C@@H]([C@@H](CC1)[C@@](C)(CCC2)[C@@H]1/C2=C/C=C(\C[C@H](C[C@@H]1O)O)/C1=C)OCCC(C)(C)O DTXXSJZBSTYZKE-WFNAWOCOSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/72—Benzo[c]thiophenes; Hydrogenated benzo[c]thiophenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D301/00—Preparation of oxiranes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
- C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
- C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
- C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
- C07D303/24—Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds
- C07D303/26—Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds having one or more free hydroxyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- JP20111573261 uses vitamin D2 as a starting material, and obtains compound X according to the method of US Pat. No. 4,866,048.
- Compound X is obtained by the action of lithium tetrahydrogenate to obtain compound V' (S configuration) and V" (R configuration), and their ratio is 35. : 65,
- Compound V' (S configuration) is the desired configuration (yield only 24%) and the efficiency of the synthesis is too low.
- the reaction temperature is preferably 0 to 10 °C.
- the molar ratio of the compound of the formula V-1 to sodium hydride and 3-(bromomethyl)-2,2-dimethyloxirane is preferably 1:1 to 3:1 to 3, more preferably It is 1:1.2:2.
- the compound of formula V-1 can be prepared by the following method:
- the molar ratio of the compound of the formula II-1 to triethylenediamine, 2,2-bipyridine and copper acetate is preferably 1:1 to 2:0.1 to 1:0.1 to 1, more preferably 1:1. :0.2:0.2.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Catalysts (AREA)
Abstract
Description
Claims (19)
- 根据权利要求1所述的化合物,其特征在于:所述羟基保护基选自硅醚类保护基。
- 根据权利要求2所述的化合物,其特征在于:所述羟基保护基选自叔丁基二甲基硅基、三甲基硅基、三乙基硅基、叔丁基二苯基硅基或三异丙基硅基。
- 根据权利要求4的方法,其特征在于:所述氧化剂选自氧气;所述催化剂选自铜催化剂。
- 根据权利要求4和5中至少一项所述的方法,其特征在于:所述催化剂为2,2-联吡啶-铜络合物。
- 根据权利要求8的方法,其特征在于:其中所述的手性助剂选自(R)-2-甲基-CBS-恶唑硼烷,(R)-2-乙基-CBS-恶唑硼烷或(R)-2-异丙基-CBS-恶唑硼烷。
- 根据权利要求8的方法,其特征在于:其中所述的硼烷选自BH3、硼烷四氢呋喃络合物、硼烷三乙胺络合物、硼烷乙醚络合物、硼烷二甲硫醚络合物或者硼烷N,N-二乙苯胺络合物。
- 根据权利要求8~10中至少一项所述的方法,其特征在于:式III化合物与手性助剂、硼烷的摩尔比为1:(0.1~1):(1~2);反应温度为-60℃~0℃。
- 根据权利要求11所述的方法,其特征在于:式III化合物与手性助剂、硼烷的摩尔比为1:0.6:1;反应温度为-20℃。
- 权利要求1~3中至少一项所述的式III化合物在制备马沙骨化醇中的用途。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2016115929A RU2650192C2 (ru) | 2013-10-12 | 2014-10-11 | Синтетическое промежуточное соединение максакальцитола, способ его получения и его применение |
CA2926961A CA2926961C (en) | 2013-10-12 | 2014-10-11 | Synthetic intermediate of maxacalcitol, preparation method therefor and use thereof |
US15/028,773 US20160237030A1 (en) | 2013-10-12 | 2014-10-11 | Synthetic intermediate of maxacalcitol, preparation method therefor and use thereof |
EP14851652.9A EP3056491B1 (en) | 2013-10-12 | 2014-10-11 | Synthetic intermediate of maxacalcitol, preparation method therefor and use thereof |
JP2016547216A JP2016534151A (ja) | 2013-10-12 | 2014-10-11 | マキサカルシトールの合成中間体及びその調製方法と使用 |
IL245018A IL245018A (en) | 2013-10-12 | 2016-04-10 | A synthetic intermediate of maxaccalitol, a method for its preparation and use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310475989.7A CN103508999B (zh) | 2013-10-12 | 2013-10-12 | 马沙骨化醇的合成中间体及其制备方法和用途 |
CN201310475989.7 | 2013-10-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015051762A1 true WO2015051762A1 (zh) | 2015-04-16 |
Family
ID=49892479
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2014/088336 WO2015051762A1 (zh) | 2013-10-12 | 2014-10-11 | 马沙骨化醇的合成中间体及其制备方法和用途 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20160237030A1 (zh) |
EP (1) | EP3056491B1 (zh) |
JP (1) | JP2016534151A (zh) |
CN (1) | CN103508999B (zh) |
CA (1) | CA2926961C (zh) |
IL (1) | IL245018A (zh) |
RU (1) | RU2650192C2 (zh) |
WO (1) | WO2015051762A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103508999B (zh) * | 2013-10-12 | 2015-05-13 | 浙江海正药业股份有限公司 | 马沙骨化醇的合成中间体及其制备方法和用途 |
CN107176918A (zh) * | 2016-03-09 | 2017-09-19 | 湖南华腾制药有限公司 | 一种马沙骨化醇的纯化方法 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4866048A (en) | 1985-08-02 | 1989-09-12 | Leo Pharmaceutical Products Ltd. | Novel vitamin D analogues |
JPH021B2 (zh) | 1983-07-18 | 1990-01-05 | Kubota Ltd | |
US5436401A (en) | 1991-12-18 | 1995-07-25 | Chugai Seiyaku Kabushiki Kaisha | 22-oxacholecalciferol derivative and process for preparing the same |
WO2001079166A1 (fr) | 2000-04-19 | 2001-10-25 | Chugai Seiyaku Kabushiki Kaisha | Derives de la vitamine d |
JP2011157326A (ja) * | 2010-02-03 | 2011-08-18 | Formosa Lab Inc | マキサカルシトール中間体およびその製造方法 |
WO2012122451A2 (en) | 2011-03-09 | 2012-09-13 | Teva Pharmaceutical Industries Ltd. | Polymorphs of maxacalcitol and process for the preparation of maxacalcitol |
CN102796134A (zh) | 2012-08-31 | 2012-11-28 | 甘肃皓天化学科技有限公司 | 一种马沙骨化醇中间体的制备方法 |
CN103508999A (zh) * | 2013-10-12 | 2014-01-15 | 浙江海正药业股份有限公司 | 马沙骨化醇的合成中间体及其制备方法和用途 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0078704B1 (en) * | 1981-11-02 | 1987-04-29 | Research Institute For Medicine And Chemistry Inc. | Intermediates in the synthesis of vitamin d derivatives |
GB9314400D0 (en) * | 1993-07-12 | 1993-08-25 | Leo Pharm Prod Ltd | Produktionsaktieselskab) chemical compounds |
KR20060038352A (ko) * | 1996-09-03 | 2006-05-03 | 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 | 비타민 디 및 스테로이드 유도체들의 합성에 사용되는중간체들 |
IT1311923B1 (it) * | 1999-04-13 | 2002-03-20 | Nicox Sa | Composti farmaceutici. |
PL376148A1 (en) * | 2002-10-23 | 2005-12-27 | Leo Pharma A/S | Vitamin d analogues, compositions comprising said analogues and their use |
US20110157322A1 (en) * | 2009-12-31 | 2011-06-30 | Broadcom Corporation | Controlling a pixel array to support an adaptable light manipulator |
-
2013
- 2013-10-12 CN CN201310475989.7A patent/CN103508999B/zh not_active Expired - Fee Related
-
2014
- 2014-10-11 RU RU2016115929A patent/RU2650192C2/ru not_active IP Right Cessation
- 2014-10-11 JP JP2016547216A patent/JP2016534151A/ja not_active Ceased
- 2014-10-11 CA CA2926961A patent/CA2926961C/en not_active Expired - Fee Related
- 2014-10-11 WO PCT/CN2014/088336 patent/WO2015051762A1/zh active Application Filing
- 2014-10-11 EP EP14851652.9A patent/EP3056491B1/en not_active Not-in-force
- 2014-10-11 US US15/028,773 patent/US20160237030A1/en not_active Abandoned
-
2016
- 2016-04-10 IL IL245018A patent/IL245018A/en not_active IP Right Cessation
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH021B2 (zh) | 1983-07-18 | 1990-01-05 | Kubota Ltd | |
US4866048A (en) | 1985-08-02 | 1989-09-12 | Leo Pharmaceutical Products Ltd. | Novel vitamin D analogues |
US5436401A (en) | 1991-12-18 | 1995-07-25 | Chugai Seiyaku Kabushiki Kaisha | 22-oxacholecalciferol derivative and process for preparing the same |
WO2001079166A1 (fr) | 2000-04-19 | 2001-10-25 | Chugai Seiyaku Kabushiki Kaisha | Derives de la vitamine d |
JP2011157326A (ja) * | 2010-02-03 | 2011-08-18 | Formosa Lab Inc | マキサカルシトール中間体およびその製造方法 |
WO2012122451A2 (en) | 2011-03-09 | 2012-09-13 | Teva Pharmaceutical Industries Ltd. | Polymorphs of maxacalcitol and process for the preparation of maxacalcitol |
CN102796134A (zh) | 2012-08-31 | 2012-11-28 | 甘肃皓天化学科技有限公司 | 一种马沙骨化醇中间体的制备方法 |
CN103508999A (zh) * | 2013-10-12 | 2014-01-15 | 浙江海正药业股份有限公司 | 马沙骨化醇的合成中间体及其制备方法和用途 |
Non-Patent Citations (2)
Title |
---|
FENG, SHI ET AL.: "Improved and Efficient Synthesis of Maxacalcitol", CHINESE CHEMICAL LETTERS, vol. 25, no. 5, 31 May 2014 (2014-05-31), pages 774, XP029023917 * |
See also references of EP3056491A4 |
Also Published As
Publication number | Publication date |
---|---|
EP3056491B1 (en) | 2018-08-08 |
IL245018A (en) | 2017-10-31 |
IL245018A0 (en) | 2016-05-31 |
CA2926961A1 (en) | 2015-04-16 |
JP2016534151A (ja) | 2016-11-04 |
CN103508999A (zh) | 2014-01-15 |
CA2926961C (en) | 2018-12-18 |
CN103508999B (zh) | 2015-05-13 |
RU2650192C2 (ru) | 2018-04-11 |
EP3056491A4 (en) | 2017-04-26 |
RU2016115929A3 (zh) | 2018-03-22 |
EP3056491A1 (en) | 2016-08-17 |
RU2016115929A (ru) | 2017-11-17 |
US20160237030A1 (en) | 2016-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5490155B2 (ja) | プロスタグランジン誘導体の製造方法 | |
CA2101310C (en) | Novel arylglycinamide derivatives and preparative processes therefor | |
WO2015051762A1 (zh) | 马沙骨化醇的合成中间体及其制备方法和用途 | |
Concellón et al. | An improved preparation of epoxides from carbonyl compounds by using diiodomethane/methyllithium: synthetic applications | |
JP5563324B2 (ja) | マキサカルシトール中間体およびその製造方法 | |
WO2016161826A1 (zh) | 一种4-异丙氨基-1-丁醇的制备方法 | |
HUE027821T2 (en) | A method for alkinylation of 16-substituted-17-ketosteroid derivatives | |
CN112479967B (zh) | 胆绿素类化合物及其制备方法和用途 | |
EP1506958B1 (en) | Process for producing shogaol and intermediates for the synthesis thereof | |
CN110734354B (zh) | 一种由醇类化合物制备联芳烃类化合物的方法 | |
JP2006522043A5 (zh) | ||
US20050209477A1 (en) | Process for producing vinyl perfluoroalkanesulfonate derivative | |
WO2018214327A1 (zh) | 一种抗癌药物羊毛甾醇衍生物的制备方法 | |
NO972257L (no) | 18-nor-vitamin D-forbindelser | |
CN114213443B (zh) | 一种由烯基硼酯制备烷基硼酯的方法 | |
CN111517939B (zh) | 一种稠合三环衍生物制备方法及中间体 | |
JP2003518089A (ja) | 24(s)−ヒドロキシビタミンd2の製造方法 | |
KR101019787B1 (ko) | 칸타잔틴의 제조방법 | |
Yan et al. | A Convenient Two-Step Synthesis of Coenzyme Q1 | |
CN116925001A (zh) | 一种抗乳腺癌药物来曲唑类似物的合成方法 | |
CN117263830A (zh) | 一种合成γ-磺酰基-α,α-二氟芳香化合物的方法 | |
JP2501604B2 (ja) | コレスタ―1,4,6−トリエン−3−オン類の製造法 | |
WO2007063930A1 (ja) | 光反応を用いるビタミンd誘導体の製法 | |
JPH03215463A (ja) | アミド化合物の製造方法 | |
JPS6034948B2 (ja) | 活性型ビタミンd↓3類の製造法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14851652 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 245018 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2926961 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2016547216 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15028773 Country of ref document: US |
|
REEP | Request for entry into the european phase |
Ref document number: 2014851652 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014851652 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2016115929 Country of ref document: RU Kind code of ref document: A |